Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis (Q44139912)

30 November 2017

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis (English)

1 reference

primary biliary cholangitis

30 November 2017

0 references

0 references

author

Giuseppe Mazzella

15

1 reference

Maria Letizia Bacchi Reggiani

30 November 2017

A Roda

14

0 references

1 reference

ORCID Public Data File 2021

author name string

E Roda

1

1 reference

30 November 2017

F Azzaroli

2

1 reference

30 November 2017

G Nigro

3

1 reference

30 November 2017

F Piazza

4

1 reference

30 November 2017

F Jaboli

5

1 reference

30 November 2017

F Ferrara

6

1 reference

30 November 2017

S Liva

7

1 reference

30 November 2017

S Giovanelli

8

1 reference

30 November 2017

A Miracolo

9

1 reference

30 November 2017

A Colecchia

10

1 reference

30 November 2017

D Festi

11

1 reference

30 November 2017

C Mazzeo

12

1 reference

30 November 2017

L Bacchi

13

1 reference

30 November 2017

1 July 2002

1 reference

Digestive and Liver Disease

30 November 2017

1 reference

30 November 2017

34

1 reference

30 November 2017

7

1 reference

30 November 2017

523-527

1 reference

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Clinical pharmacokinetics of therapeutic bile acids.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Improved intestinal absorption of an enteric-coated sodium ursodeoxycholate formulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Bioavailability study of a new, sinking, enteric-coated ursodeoxycholic acid formulation

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980112-8

7 January 2021

10.1016/S1590-8658(02)80112-8

Identifiers

DOI

1 reference

30 November 2017

1 reference